Evaluation of Serum Cytokines Levels and the Role of Cannabidiol Treatment in Animal Model of Asthma

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Vuolo, Francieli ^a   Petronilho, Fabricia ^b   Sonai, Beatriz ^a   Ritter, Cristiane ^a   Hallak, Jaime E C ^c   Zuardi, Antonio Waldo ^c   Crippa, José A ^c   Dal Pizzol, Felipe ^a  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^b UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; OVALBUMIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; IMMUNOMODULATION; MALE; NONHUMAN; OVALBUMIN-INDUCED AIRWAY INFLAMMATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; ANIMAL; BLOOD; DISEASE MODEL; IMMUNOLOGY; WISTAR RAT;

ANIMALIA; RATTUS NORVEGICUS;

ANIMALS; ASTHMA; CANNABIDIOL; CYTOKINES; DISEASE MODELS, ANIMAL; MALE; OVALBUMIN; RATS; RATS, WISTAR;

EID: 84935880515     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/538670     Document Type: Article

References (26)

1. D. Laughter, J. A. Istvan, S. J. Tofte, and J. M. Hanifin, "The prevalence of atopic dermatitis inOregon schoolchildren," Journal of the American Academy of Dermatology, vol. 43, no. 4, pp. 649-655, 2000.
2. J. Ker and T. V. Hartert, "The atopicmarch:whats the evidence?" Annals of Allergy, Asthma and Immunology, vol. 103, no. 4, pp. 282-289, 2009.
3. S. T. Holgate, "Pathogenesisof asthma," Clinical and Experimental Allergy, vol. 38, no. 6, pp. 872-897, 2008.
4. J. M. Cunha, E. A. Carlini, A. E. Pereira et al., "Chronic administration of cannabidiol to healthy volunteers and epileptic patients," Pharmacology, vol. 21, no. 3, pp. 175-185, 1980.
5. S. Burtein, "Cannabidiol (CBD) and its analogs: a reviewof their effects on inflammation," Bioorganic and Medicinal Chemistry, vol. 1, pp. 1377-1385, 2015.
6. R. G. Pertwee, "The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin," British Journal of Pharmacology, vol. 153, no. 2, pp. 199-215, 2008.
7. K. F. Chung, "New treatments for severe treatment-resistant asthma: targeting the right patient,"TheLancet RespiratoryMedicine, vol. 1, no. 8, pp. 639-652, 2013.
8. A. W. Zuardi, J. A. S. Crippa, J. E. C. Hallak, F. A. Moreira, and F. S. Guimaraes, "Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug," Brazilian Journal of Medical and Biological Research, vol. 39, no. 4, pp. 421-429, 2006.
9. M. M. Bergamaschi, R. H. C. Queiroz, A. W. Zuardi, and J. A. S. Crippa, "Safety and side effects of cannabidiol, a Cannabis sativa constituent," CurrentDrug Safety, vol. 6, no. 4, pp. 237-249, 2011.
10. A. W. Zuardi, "Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action," Revista Brasileira de Psiquiatria, vol. 30, no. 3, pp. 271-280, 2008.
11. R. Mechoulam, L. A. Parker, and R. Gallily, "Cannabidiol: an overview of some pharmacological aspects," Journal of Clinical Pharmacology, vol. 42, no. 11, pp. 11S-19S, 2002.
12. A. Ribeiro, V. Ferraz-De-Paula, M. L. Pinheiro et al., "Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosineA2β receptor,"EuropeanJournal of Pharmacology, vol. 678, no. 1-3, pp. 78-85, 2012.
13. A. T. Nials and S. Uddin, "Mouse models of allergic asthma: acute and chronic allergen challenge," DiseaseModels andMechanisms, vol. 1, no. 4-5, pp. 213-220, 2008.
14. M. Humbert, S. R. Durham, S. Ying et al., "IL-4 and IL-5mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against intrinsic asthma being a distinct immunopathologic entity," American Journal of Respiratory and Critical CareMedicine, vol. 154, no. 5, pp. 1497-1504, 1996.
15. T. C. Kotsimbos, P. Ernst, and Q. A. Hamid, "Interleukin-13 and interleukin-4 are coexpressed in atopic asthma," Proceedings of the Association of American Physicians, vol. 108, no. 5, pp. 368-373, 1996.
16. S. Ying, M. Humbert, J. Barkans et al., "Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics," The Journal of Immunology, vol. 158, no. 7, pp. 3539-3544, 1997.
17. T. G. Uhm, B. S. Kim, and Y. S. Chung II, "Eosinophil development, regulation of eosinophil-specific genes, and role of eosinophils in the pathogenesis of asthma," Allergy, Asthma and Immunology Research, vol. 4, no. 2, pp. 68-79, 2012.
18. F. A. DiGiovanni, R. Ellis, J. Wattie, J. A. Hirota, D. S. Southam, and M. D. Inman, "Concurrent dual allergen exposure and its effects on airway hyperresponsiveness, inflammation and remodeling in mice," DMM Disease Models and Mechanisms, vol. 2, no. 5-6, pp. 275-282, 2009.
19. S. Wenzel, D. Wilbraham, R. Fuller, E. B. Getz, and M. Longphre, "Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies," The Lancet, vol. 370, no. 9596, pp. 1422-1431, 2007.
20. J. van Snick, "Interleukin-6: an overview," Annual Review of Immunology, vol. 8, pp. 253-278, 1990.
21. S. C. Erzurum, "Inhibition of tumor necrosis factor β for refractory asthma," The New England Journal of Medicine, vol. 354, no. 7, pp. 754-758, 2006.
22. P. Flood-Page, C. Swenson, I. Faiferman et al., "A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma," The American Journal of Respiratory and Critical Care Medicine, vol. 176, no. 11, pp. 1062-1071, 2007.
23. J. Corren, R. F. Lemanske Jr., N. A. Hanania et al., "Lebrikizumab treatment in adults with asthma," The New England Journal of Medicine, vol. 365, no. 12, pp. 1088-1098, 2011.
24. J. M. Parker, C. K. Oh, C. LaForce et al., "Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma," BMC Pulmonary Medicine, vol. 11, article 14, 2011.
25. V. L. Hegde, U. P. Singh, P. S. Nagarkatti, and M. Nagarkatti, "Critical role of mast cells and peroxisome proliferator-activated receptor γ in the induction ofmyeloid-derived suppressor cells bymarijuana cannabidiol in vivo,"The Journal of Immunology, 2015.
26. B. L. F. Kaplan, A. E. B. Springs, and N. E. Kaminski, "The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT)," Biochemical Pharmacology, vol. 76, no. 6, pp. 726-737, 2008.